Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Clinical Trial of Multiple Doses of GR2301 Injection in Healthy Adult Trial Participants in China.
Sponsor: Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Summary
This is a randomized, double-blind, placebo-controlled Phase I clinical trial evaluating the safety, tolerability, pharmacokinetics and immunogenicity characteristics of GR2301 injection in healthy adult subjects in China. The Multiple doses will be gradually escalated.
Official title: A Randomized, Double-blind, Placebo-controlled Phase Ib Clinical Trial Evaluating the Safety, Tolerability, Pharmacokinetics, and Immunogenicity Profiles of Multiple Doses of GR2301 Injection in Healthy Adult Trial Participants in China.
Key Details
Gender
All
Age Range
18 Years - 45 Years
Study Type
INTERVENTIONAL
Enrollment
36
Start Date
2026-06
Completion Date
2027-07
Last Updated
2026-06-15
Healthy Volunteers
Yes
Conditions
Interventions
GR2301 injection
IL15 monoclonal antibody
Locations (1)
Beijing Tongren Hospital Affiliated to Capital Medical University
Beijing, Beijing Municipality, China